RainPath

Based in France, RainPath operates as a provider of advanced biopsy analysis through innovative AI technology, enhancing the accuracy and efficiency of tissue analysis for healthcare institutions. Founded in 2025 and headquartered in Paris, France, RainPath specializes in AI-powered biopsy analysis. The company has focused on developing virtual staining technology to streamline histopathology workflows. They recently raised EUR 2.

5 million in funding on July 10, 2025, from investor Teampact Ventures, marking a significant milestone in their funding journey. RainPath specializes in advanced biopsy analysis through its innovative AI-powered virtual staining technology. This core product enables pathologists to enhance the accuracy and efficiency of tissue analysis by simulating the staining process digitally, thereby eliminating the need for traditional wet staining methods. The end use cases primarily focus on improving diagnostic precision and workflow in histopathology labs, thereby facilitating better patient outcomes.

RainPath's technology caters to a diverse client base, including hospitals, diagnostic laboratories, and research institutions across North America and Europe. By providing a solution that streamlines the biopsy analysis process, RainPath positions itself as a pivotal player in the healthcare sector, aiming to enhance the diagnostic capabilities of its users. RainPath generates revenue through a subscription-based model tailored for healthcare institutions and laboratories that utilize its AI-driven virtual staining services. Clients typically enter into annual contracts, allowing them to access the technology and receive continuous updates and support.

Specific pricing plans are structured to accommodate varying levels of usage, ensuring that both small and large institutions can benefit from the service. The flagship product, which embodies the company’s commitment to innovation in pathology, plays a significant role in these agreements, as clients rely on it for their core diagnostic processes. Revenue is derived directly from these service agreements, reflecting a B2B focus that emphasizes long-term partnerships with its clients. RainPath plans to utilize the EUR 2.

5 million raised in July 2025 to further develop its AI technologies and launch new products aimed at enhancing its biopsy analysis capabilities. The company is targeting expansion into North American and European markets, maintaining its focus on healthcare institutions. Specific product launches and timelines have yet to be disclosed, but the funding is expected to support these growth initiatives.